BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...Inc. Adaptive Biotechnologies Corp. [MERGED] AstraZeneca plc Aadi Bioscience Inc. Verily Life Sciences LLC Broad Institute of MIT and Harvard Microsoft Corp. Taizhou EOC Pharma Co. Ltd. Turning...
BioCentury | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

...MabSpace Biosciences Co. Ltd. (see "Hangzhou Just, MabSpace Merging" ). EOC raises $71M series C EOC Pharma...
...dehydrogenase; IL-13RA1 (IL-13Ra, CD213A1) - Interleukin-13 receptor alpha 1; VEGF - Vascular endothelial growth factor BC Staff Taizhou EOC Pharma Co. Ltd. Transcenta...
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...with HDAC inhibitors in patient-derived xenograft (PDX) and organoid models of ovarian cancer. Bayer AG, EOC Pharma...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...with vehicle. Next steps include testing entinostat in models of other rhabdomyosarcoma subtypes. Bayer AG, EOC Pharma...
BioCentury | Nov 10, 2017
Financial News

EOC Pharma raises $32M series B

...On Nov. 7, EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led...
...Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China. EOC Pharma...
...Inc. (San Francisco, Calif.). EOC Pharma Group, Shanghai, China Jennie Walters ACT Biotech Inc. Edding Group Co. Ltd. Syndax Pharmaceuticals Inc. Taizhou EOC Pharma Co. Ltd. Histone...
BioCentury | Nov 7, 2017
Financial News

EOC Pharma raises $32M series B

...Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China. EOC Pharma...
...previously Eddingpharm's CBO, said the company has raised about $47 million to date. Next year, EOC Pharma...
...an oral histone deacetylase (HDAC) inhibitor, and telatinib is a small molecule VEGF receptor inhibitor. EOC Pharma...
Items per page:
1 - 6 of 6
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...Inc. Adaptive Biotechnologies Corp. [MERGED] AstraZeneca plc Aadi Bioscience Inc. Verily Life Sciences LLC Broad Institute of MIT and Harvard Microsoft Corp. Taizhou EOC Pharma Co. Ltd. Turning...
BioCentury | Dec 3, 2019
Financial News

Dec. 2 Financial Quick Takes: Kodiak gains on royalty deal; plus Clover, Aslan, Transcenta, EOC, Hui-Gene and ViGeneron

...MabSpace Biosciences Co. Ltd. (see "Hangzhou Just, MabSpace Merging" ). EOC raises $71M series C EOC Pharma...
...dehydrogenase; IL-13RA1 (IL-13Ra, CD213A1) - Interleukin-13 receptor alpha 1; VEGF - Vascular endothelial growth factor BC Staff Taizhou EOC Pharma Co. Ltd. Transcenta...
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...with HDAC inhibitors in patient-derived xenograft (PDX) and organoid models of ovarian cancer. Bayer AG, EOC Pharma...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Cancer

...with vehicle. Next steps include testing entinostat in models of other rhabdomyosarcoma subtypes. Bayer AG, EOC Pharma...
BioCentury | Nov 10, 2017
Financial News

EOC Pharma raises $32M series B

...On Nov. 7, EOC Pharma Group (Shanghai, China) raised $32 million in a series B round led...
...Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China. EOC Pharma...
...Inc. (San Francisco, Calif.). EOC Pharma Group, Shanghai, China Jennie Walters ACT Biotech Inc. Edding Group Co. Ltd. Syndax Pharmaceuticals Inc. Taizhou EOC Pharma Co. Ltd. Histone...
BioCentury | Nov 7, 2017
Financial News

EOC Pharma raises $32M series B

...Taikang. Fellow new investor H&Q Asia Pacific also participated, as did existing investor Sequoia China. EOC Pharma...
...previously Eddingpharm's CBO, said the company has raised about $47 million to date. Next year, EOC Pharma...
...an oral histone deacetylase (HDAC) inhibitor, and telatinib is a small molecule VEGF receptor inhibitor. EOC Pharma...
Items per page:
1 - 6 of 6